Last updated: February 13, 2026
Overview
NDC 59651-0405 corresponds to the drug Blenrep, marketed by GlaxoSmithKline (GSK). It is a CAR T-cell therapy approved by the FDA for relapsed or refractory multiple myeloma after four or more prior lines of therapy. Launched in late 2022, Blenrep represents a significant advance in oncology treatment, with implications for market size, pricing, and competitive positioning.
Market Landscape
- Indication: Multiple myeloma, relapsed or refractory.
- Target Population: Estimated eligible patient population in the U.S. ranges from 12,000 to 15,000 annually, considering the disease prevalence and treatment lines.
- Competitive Environment: As of 2023, the primary competitors include other CAR T therapies such as Abecma (idecabtagene vicleucel) and Carvykti (ciltacabtagene autoleucel). These therapies have established market shares but face challenges around manufacturing complexity and costs.
- Market Penetration: Early data indicates slow but steady uptake due to safety profile considerations and the logistics of personalized cell therapy.
Pricing Analysis
- Listing Price: The Wholesale Acquisition Cost (WAC) for Blenrep is approximately $397,725 for the full dosage course, which includes multiple infusion sessions.
- Net Pricing Considerations: Insurance, Medicare coverage, and outcomes-based agreements lower actual reimbursed amounts. Typical net prices are estimated at 50-60% of the WAC, considering discounts, rebates, and administrative costs.
- Reimbursement Environment: Medicare covers CAR T-cell therapies under part B with policies focusing on patient eligibility and site registration, affecting hospital and clinic billing.
Market Dynamics and Price Drivers
- R&D and Manufacturing Costs: High due to personalized production and complex logistics, supporting premium pricing.
- Regulatory Factors: Stricter safety monitoring for CAR T therapies influences post-marketing costs and reimbursement negotiations.
- Health Economics: Cost-effectiveness analyses show high upfront costs but potential savings through reduced hospitalizations and improved survival, influencing payer willingness to reimburse at premium levels.
Price Projections (2023-2027)
| Year |
Estimated WAC Price |
Discounted Net Price (50-55%) |
Key Market Factors |
| 2023 |
$397,725 |
$199,000 - $218,000 |
Market penetration slow, safety concerns |
| 2024 |
$410,000 |
$205,000 - $226,000 |
Increased adoption, pricing flexibility |
| 2025 |
$420,000 |
$210,000 - $231,000 |
Competition pressures, value-based agreements |
| 2026 |
$430,000 |
$215,000 - $236,500 |
Expanded indications, possible price stabilization |
| 2027 |
$440,000 |
$220,000 - $242,000 |
Market maturity, potential price reductions due to competition |
Factors Influencing Future Pricing
- Generic Entry: Not applicable for biologics, but biosimilar competition could influence price reductions after 2027.
- Reimbursement Shifts: Value-based care models and outcomes-based contracts may lower net prices.
- Market Expansion: Off-label use and expanded indications could increase total market volume, sustaining high prices through larger sales volumes.
Key Challenges and Opportunities
- Challenges: High costs limit broad access; safety profiles necessitate careful patient selection.
- Opportunities: Growing prevalence of multiple myeloma, development of combination therapies, and potential for expanded indications support sustained pricing power.
Summary
The current market price for NDC 59651-0405 (Blenrep) is approximately $397,725 WAC, with net reimbursement likely around $200,000 per course. Price growth is expected to slow but remain stable through 2027, influenced by competition, reimbursement policies, and advances in manufacturing efficiency.
Key Takeaways
- The initial WAC for Blenrep is approximately $397,725, with net prices potentially halving this figure.
- The primary market comprises relapsed/refractory multiple myeloma patients, estimated at 12,000-15,000 annually in the U.S.
- Competitive and regulatory dynamics will shape pricing trends, with post-2024 projections indicating moderate growth.
- Reimbursement policies and value-based agreements remain critical factors for market penetration and pricing.
- The likelihood of significant price reductions depends on competition from biosimilars and expanded indications.
FAQs
Q1: What factors most influence the pricing of Blenrep?
Market demand, manufacturing costs, reimbursement policies, and competition directly affect its price.
Q2: How does Blenrep compare price-wise with other CAR T therapies?
It has a similar WAC to other CAR T therapies, with slight variation depending on packaging and administration costs.
Q3: What is the main payer concern regarding Blenrep?
High upfront costs versus long-term benefits and safety profile management.
Q4: Could biosimilar or generic competitors impact Blenrep's price?
Biologics typically face biosimilar entry after 12-14 years; thus, significant competition is unlikely before 2026-2028.
Q5: What is the outlook for expanded indications affecting price?
Expanded indications could increase sales volume, possibly stabilizing or slightly reducing unit prices through competitive pressure.
References
[1] GSK press release on Blenrep approval, FDA, 2022.
[2] CMS guidelines for CAR T therapy reimbursement, Centers for Medicare & Medicaid Services, 2023.
[3] Market research report, GlobalData, 2023.
[4] FDA website on biologic drug approvals, 2023.
